AtG Therapeutics

www.atgtx.com ↗ ·Barcelona ·Seed

AtG Therapeutics is a Barcelona-based preclinical-stage biotech company that develops cancer drugs and patient-selection biomarkers aimed at tumour adaptation vulnerabilities, for patients with advanced cancers such as kidney, colorectal and breast cancer, whether untreated or resistant to treatment. Its pipeline includes AtG 153, a first-in-class small-molecule intracellular inhibitor that targets tumour cell metabolism, and AngioDxPredict, a biomarker tool for identifying the patients most likely to respond to treatment. The company was founded in 2019 as a spin-off of the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO). In July 2022 it raised a €556,000 seed round from Blue Goose Capital, the WA4STEAM and StapleCat/Inveniam angel groups and several international scientists, and in 2024 it won €1.36 million in Eurostars funding to develop its renal cancer inhibitor.

Founded

2019

Founders

Total funds raised

€556K

SectorsBiotechnology, Oncology, Drug Discovery, Diagnostics & Biomarkers Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Bart Huisken

Co-Founder & Business and Financial Strategist

Gabriela Jiménez

Co-Founder & COO

Oriol Casanovas

Co-Founder & Interim CEO

Global models 5

Relay Therapeutics

United States · relaytx.com ↗

Precision-oncology drug developer building first-in-class small molecules for defined groups of patients chosen by biomarker, with value built through clinical progress and licensing.

~$520M (pre-IPO)Comparable

Erasca

United States · www.erasca.com ↗

Develops small-molecule cancer drugs aimed at the ways tumours adapt and resist treatment, paired with patient selection.

~$300M (pre-IPO)Comparable

Scorpion Therapeutics

United States · scorpiontx.com ↗

VC-backed oncology company developing small molecules against tumour weak points for patients picked by biomarker, sold in a pharma deal.

~$270MComparable

Boundless Bio

United States · boundlessbio.com ↗

Targets an adaptation mechanism that tumours use to resist treatment, using its own companion diagnostic to select patients, much like AtG pairs AtG 153 with AngioDxPredict.

~$250M (pre-IPO)Comparable

Tango Therapeutics

United States · www.tangotx.com ↗

Precision-oncology company discovering small molecules that exploit tumour weak points in genetically defined, often treatment-resistant patient groups.

~$115M (pre-listing)Comparable